CardioBoyo AT
Antithrombotic & Anticoagulation Assistant
v1.1
CardioBoyo AT
Antithrombotic & Anticoagulation Assistant — evidence-based clinical decision support for antiplatelet therapy, anticoagulation, PCI, and atrial fibrillation management.
ESC 2024 · ACC/AHA 2025 · EHRA 2024 · ARC-HBR 2023 · JACC Asia 2025 · Part of the CardioBoyo clinical platform ecosystem.
Clinical modules
AF Manager
CHA₂DS₂-VA · OAC selection
PCI Protocol
DAPT · ARC-HBR · East Asian
Anticoagulation
VTE · OAC dosing · CKD
Perioperative
Hold · Bridge · Restart
Score Library
14+ validated scores
Drug Reference
EHRA 2024 · ACC/AHA 2025
PlatformCardioBoyo AT v1.1 · 2025
Websitecardioboyo.com/at
EcosystemCardioBoyo Platform
Evidence base
ESC Guidelines — Atrial Fibrillation2024
ACC/AHA ACS Guideline2025
EHRA Practical Guide on NOACs2024
ARC-HBR Consensus Document2023
Antiplatelet Therapy — East Asians (JACC Asia)2025
For clinical decision support only. All recommendations are guideline-based and do not replace physician clinical judgement or specialist consultation where indicated.
References & evidence sources 12 sources
▾
Primary guidelines
2024ESC Guidelines for AF Management — Van Gelder IC et al. Eur Heart J 2024
2025ACC/AHA ACS Guideline — J Am Coll Cardiol 2025
2023ESC ACS Guidelines — Byrne RA et al. Eur Heart J 2023
Practical guides & consensus
2024EHRA Practical Guide on NOACs — Steffel J et al. Europace 2024
2023ARC-HBR Consensus — Urban P et al. Eur Heart J 2023
2023ASH VTE Guidelines — Blood Adv 2023
2022ESC Perioperative CV Assessment — Eur Heart J 2022
2022ESRA Regional Anaesthesia Guidance — 2022
Population-specific evidence
2025Antiplatelet Therapy for East Asians — Gong et al. JACC: Asia 2025;5(7):821–846
Landmark trials
2019AUGUSTUS trial — Lopes RD et al. N Engl J Med 2019
2021MASTER DAPT — Valgimigli M et al. N Engl J Med 2021
2022STOP-DAPT2-ACS — Watanabe H et al. JAMA 2022
CardioBoyo AT v1.1 Evidence base: Jan 2025
CardioBoyo AT
Antithrombotic & Anticoagulation Assistant
v1.1
Clinical modules
Select a pathway to begin your assessment
AF Manager
CHA₂DS₂-VA · OAC
PCI Protocol
DAPT · ARC-HBR
Anticoagulation
VTE · OAC · CKD
Perioperative
Hold · Bridge
Score Library
14+ validated scores
Drug Reference
EHRA 2024 dosing
Clinical disclaimer
This platform provides evidence-based decision support only. All recommendations must be interpreted in the full clinical context. This tool does not replace physician judgement or specialist consultation.
Home
Scores
Drugs
About
AF Manager
Step 1 of 3 · Patient profile
Patient profile
eGFR auto-calculated from serum creatinine — CKD-EPI 2021
Demographics
Age
yrs
Weight optional
kg
Sex
Male
Female
Serum creatinine auto-eGFR
mg/dL
eGFR calculated automatically using CKD-EPI 2021 (race-free · KDIGO 2024 recommended)
CHA₂DS₂-VA components — tap to select (ESC 2024)
Heart failure / LV dysfunction
Hypertension
Diabetes mellitus
Prior stroke / TIA / thromboembolism
Vascular disease (MI, PAD, aortic plaque)
Age 65–74 years
HAS-BLED bleeding risk factors
Uncontrolled hypertension (SBP >160)
Renal dysfunction
Liver dysfunction
Prior stroke history
Prior major bleeding / anaemia
Labile INR (if on warfarin)
Age >65 years
NSAIDs / antiplatelets
Alcohol use
Valve status
Mechanical prosthetic valve
Rheumatic mitral stenosis
AF Manager
Step 2 of 3 · Risk scores
Risk assessment
Calculated from entered profile · ESC 2024
CHA₂DS₂-VA score ESC 2024 — sex category removed
0
Low risk
OAC not recommended
0
1
≥2 — OAC recommended
—
HAS-BLED score
0
Low bleed risk
Identify and correct modifiable factors
Ischemic riskBleeding risk
ARC-HBR status
Completing assessment…
AF Manager
Step 3 of 3 · Recommendation
Recommendation
Based on ESC 2024 guidelines
Copied to clipboard!
Evidence & references 9 sources
▾
Primary guidelines
2024ESC Guidelines for AF Management — Van Gelder IC et al. Eur Heart J 2024
2024ACC/AHA/ACCP/HRS AF Guideline — Joglar JA et al. J Am Coll Cardiol 2024
Practical guides
2024EHRA Practical Guide on NOACs — Steffel J et al. Europace 2024
2023ARC-HBR Consensus — Urban P et al. Eur Heart J 2023
Supporting trials
2019AUGUSTUS — Lopes RD et al. N Engl J Med 2019 (AF + PCI · apixaban dual Rx)
2016PIONEER AF-PCI — Gibson CM et al. N Engl J Med 2016
2017REDUAL-PCI — Cannon CP et al. N Engl J Med 2017
2011ARISTOTLE — Granger CB et al. N Engl J Med 2011 (apixaban vs warfarin)
2009RE-LY — Connolly SJ et al. N Engl J Med 2009 (dabigatran)
CardioBoyo AT v1.1 Evidence base: Jan 2025
PCI Protocol
DAPT · ARC-HBR · Antithrombotic
PCI assessment
Enter presentation context, patient profile, and risk factors
Population context
General population
East / Southeast Asian
East Asian context activates JACC Asia 2025 modified HBR criteria and clopidogrel-preferred pathway where appropriate.
Clinical presentation
ACS
Elective PCI
STEMI
NSTEMI
UA
Patient parameters
Age
yrs
Weight
kg
Sex
M
F
Scr auto-eGFR
mg/dL
Hb g/dL
Platelets ×10⁹/L
ARC-HBR major criteria — 1 = HBR confirmed
Long-term OAC required (AF / VTE / valve)
Prior intracranial haemorrhage (any time)
Major bleed requiring hospitalisation — prior 6 months
Active malignancy — prior 12 months
Liver cirrhosis with portal hypertension
HF — elderly patient undergoing PCI (EA)
ARC-HBR minor criteria — 2 = HBR confirmed
Age ≥75 years
Long-term NSAIDs / steroids
Bleed requiring hospitalisation — prior 12 months
Any prior ischaemic stroke
High ischemic risk features (ACS — dual-axis assessment)
Complex PCI (left main / 3-vessel / bifurcation / long stent >60mm)
Prior stent thrombosis on antiplatelet therapy
Multivessel CAD with residual disease
LVEF <35%
Insulin-dependent DM
Premature CAD <45y (EA)
Prior stroke / TIA — prasugrel contraindicated
AF requiring long-term OAC?
No AF / no OAC needed
AF — OAC required
PCI Protocol
DAPT & antithrombotic recommendation
DAPT recommendation
Based on ESC 2023 · ACC/AHA 2025 · ARC-HBR 2023
Copied!
Evidence & references 12 sources
▾
Primary guidelines
2023ESC ACS Guidelines — Byrne RA et al. Eur Heart J 2023
2025ACC/AHA ACS Guideline — J Am Coll Cardiol 2025
2023ESC Revascularisation Guidelines — Vrints C et al. Eur Heart J 2023
2024ESC AF Guidelines (AF + PCI section) — Eur Heart J 2024
Consensus
2023ARC-HBR Consensus — Urban P et al. Eur Heart J 2023
Population-specific
2025Antiplatelet Therapy for East Asians — Gong et al. JACC: Asia 2025;5(7):821–846
Key trials
2021MASTER DAPT — Valgimigli M et al. N Engl J Med 2021
2022STOP-DAPT2-ACS — Watanabe H et al. JAMA 2022
2019TWILIGHT — Mehran R et al. N Engl J Med 2019
2019AUGUSTUS — Lopes RD et al. N Engl J Med 2019
2016PIONEER AF-PCI — Gibson CM et al. N Engl J Med 2016
2023HOST-EXAM — Koo BK et al. Lancet 2021 (clopidogrel vs aspirin monotherapy)
CardioBoyo AT v1.1 Evidence base: Jan 2025
Anticoagulation
VTE · Dosing · Renal adjustment
Anticoagulation assessment
Select indication and enter patient parameters
Indication
VTE (DVT / PE)
Cancer-associated thrombosis
VTE treatment phase
Acute (<7 days)
Early (1–6 months)
Extended (>6 months)
Patient parameters
Age
yrs
Weight optional
kg
Sex
M
F
Scr auto-eGFR
mg/dL
Special situations
Pregnancy / childbearing age
High GI bleed risk
Anticoagulation
Dosing recommendation
Dosing recommendation
ESC 2023 · EHRA 2024 · ASH 2023
Copied!
Evidence & references 10 sources
▾
Primary guidelines
2023ESC PE & VTE Guidelines — Konstantinides SV et al. Eur Heart J 2023
2023ASH VTE Guidelines — Blood Adv 2023
Practical guides
2024EHRA Practical Guide on NOACs — Steffel J et al. Europace 2024
2023ISTH Cancer-Associated Thrombosis — Lancet Oncol 2023
Key trials
2013AMPLIFY-EXT — Agnelli G et al. N Engl J Med 2013
2018HOKUSAI-Cancer — Raskob GE et al. N Engl J Med 2018
2018SELECT-D — Young AM et al. J Clin Oncol 2018
CardioBoyo AT v1.1 Evidence base: Jan 2025
Perioperative
Hold · Bridge · Restart timing
Perioperative plan
Enter anticoagulant, surgical risk, and patient eGFR
Prior PCI history
Prior PCI — yes
No prior PCI
Coronary artery disease
Known CAD — yes
No known CAD
Current anticoagulant
Apixaban
Rivaroxaban
Dabigatran
Warfarin
LMWH
Surgery bleeding risk
Low risk
Moderate risk
High risk
Low: cataract, minor dental, endoscopy without polypectomy. Moderate: colonoscopy, abdominal, orthopaedic. High: cardiac, neurosurgery, major cancer surgery.
eGFR (critical for dabigatran hold windows)
Serum creatinine auto-eGFR
yrs
mg/dL
Male
Female
Thromboembolic risk (for bridging decision)
Low / moderate TE risk
High TE risk (mech. valve / recent VTE)
Perioperative
Hold & restart timeline
Perioperative plan
ESC 2022 · EHRA 2024 · ESRA 2022
Copied!
Evidence & references 10 sources
▾
Primary guidelines
2022ESC Cardiovascular Assessment — Non-Cardiac Surgery — Eur Heart J 2022
2022ACC/AHA Perioperative Cardiovascular Management — J Am Coll Cardiol 2022
2025ACC/AHA ACS Guideline — Perioperative antiplatelet section. J Am Coll Cardiol 2025
Practical guides
2024EHRA Practical Guide on NOACs — Steffel J et al. Europace 2024
2022ESRA Regional Anaesthesia Guidance — Eur J Anaesthesiol 2022
Key trials
2015BRIDGE Trial — Douketis JD et al. N Engl J Med 2015 (no bridging in AF)
2014POISE-2 Trial — Devereaux PJ et al. N Engl J Med 2014 (aspirin initiation in NCS: no benefit, increased bleeding)
CardioBoyo AT v1.1 Evidence base: Jan 2025
Score Library
14 validated clinical scores
Score library
Tap any score to calculate · Evidence class shown for each
Atrial fibrillation
CHA₂DS₂-VAClass I-A · ESC 2024
Stroke risk in AF — 2024 update: female sex removed as independent scoring point
Van Gelder IC et al. Eur Heart J 2024 · Updated 2024
HAS-BLEDClass IIa-B
Bleeding risk in AF — identifies correctable risk factors, not a contraindication to OAC
Pisters R et al. Chest 2010
SAMe-TT₂R₂Class IIa-B
VKA suitability — predicts TTR quality on warfarin. Score >2 = prefer DOAC
Apostolakis S et al. Chest 2013
Acute coronary syndrome
GRACE 2.0Class I-B
ACS in-hospital and 6-month / 1-year mortality prediction
Fox KA et al. BMJ 2014
CRUSADEClass IIa-B
In-hospital major bleeding risk in ACS patients
Subherwal S et al. Circulation 2009
PRECISE-DAPTClass I-B
DAPT bleeding risk — score ≥25 indicates HBR, gates short DAPT pathway
Costa F et al. Lancet 2017
DAPT ScoreClass IIb-B
Ischemic vs bleeding benefit of extended DAPT beyond 12 months (score ≥2 favours extension)
Yeh RW et al. JAMA 2016
VTE / Pulmonary embolism
Wells PE ScoreClass I-B
Pre-test probability for pulmonary embolism — 2-level and 3-level versions
Wells PS et al. Lancet 1999
PESI / sPESIClass I-B
PE severity and 30-day mortality — simplified (sPESI) for bedside use
Jiménez D et al. Arch Intern Med 2010
RIETE ScoreClass IIa-B
Bleeding risk during anticoagulation for VTE — guides duration decisions
Ruíz-Giménez N et al. Thromb Haemost 2008
Bleeding risk — PCI
ARC-HBR CriteriaClass I-A · ESC 2023
High bleeding risk for PCI — 1 major OR 2 minor criteria confirms HBR
Urban P et al. Circulation 2019 · Endorsed ESC 2023 · JACC Asia 2025 (EA modifications)
ABC BleedingClass IIb-B
Biomarker-based bleeding risk in AF — superior in populations with biomarker access
Hijazi Z et al. Lancet 2016
Drug Reference
EHRA 2024 · ACC/AHA 2025 dosing
Drug reference
Select a drug — dosing, renal adjustment, interactions
Select drug
Apixaban
Rivaroxaban
Dabigatran
Edoxaban
Warfarin
About
CardioBoyo AT v1.1
About CardioBoyo AT
Antithrombotic & Anticoagulation Assistant
Platform information
PlatformCardioBoyo AT v1.1
Evidence baseJanuary 2025
EcosystemCardioBoyo Platform
Websitecardioboyo.com/at
Evidence sources
ESC AF Guidelines2024
ACC/AHA ACS Guideline2025
EHRA Practical Guide NOACs2024
ARC-HBR Consensus2023
ESC ACS Guidelines2023
ESC PE / VTE Guidelines2023
ASH VTE Guidelines2023
ESC Perioperative CV2022
JACC Asia — East Asian Antiplatelet2025
Clinical disclaimer
CardioBoyo AT is a clinical decision support tool. All recommendations are evidence-based but must be interpreted in the context of the individual patient's full clinical picture, including factors not captured in this tool. This platform does not constitute medical advice and should not be used as the sole basis for clinical decisions. Specialist consultation should be sought where indicated.
Privacy & data
No patient data is stored or transmitted. All calculations occur locally in your browser. Data is cleared when you close or refresh this tab. No analytics on patient inputs, no server communication.